MA42623A - Inhibiteurs de la tyrosine kinase de bruton - Google Patents
Inhibiteurs de la tyrosine kinase de brutonInfo
- Publication number
- MA42623A MA42623A MA042623A MA42623A MA42623A MA 42623 A MA42623 A MA 42623A MA 042623 A MA042623 A MA 042623A MA 42623 A MA42623 A MA 42623A MA 42623 A MA42623 A MA 42623A
- Authority
- MA
- Morocco
- Prior art keywords
- tyrosine kinase
- kinase inhibitors
- bruton tyrosine
- bruton
- inhibitors
- Prior art date
Links
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 title 1
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 title 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562169941P | 2015-06-02 | 2015-06-02 | |
| US201562169935P | 2015-06-02 | 2015-06-02 | |
| US201562169945P | 2015-06-02 | 2015-06-02 | |
| US201562249336P | 2015-11-01 | 2015-11-01 | |
| US201562249338P | 2015-11-01 | 2015-11-01 | |
| US201562249340P | 2015-11-01 | 2015-11-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA42623A true MA42623A (fr) | 2018-06-20 |
Family
ID=57441893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA042623A MA42623A (fr) | 2015-06-02 | 2016-06-02 | Inhibiteurs de la tyrosine kinase de bruton |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20180305348A1 (fr) |
| EP (1) | EP3310776A4 (fr) |
| JP (1) | JP2018522823A (fr) |
| KR (1) | KR20180021740A (fr) |
| CN (1) | CN107709315A (fr) |
| AU (2) | AU2016270907B2 (fr) |
| BR (1) | BR112017025986A2 (fr) |
| CA (1) | CA2987054A1 (fr) |
| IL (1) | IL255831A (fr) |
| MA (1) | MA42623A (fr) |
| MX (1) | MX2017015574A (fr) |
| RU (1) | RU2017145650A (fr) |
| SG (1) | SG10201911523YA (fr) |
| WO (1) | WO2016196776A2 (fr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017383236B2 (en) * | 2016-12-21 | 2022-02-10 | Acerta Pharma B.V. | Imidazopyrazine inhibitors of Bruton's tyrosine kinase |
| KR101956815B1 (ko) * | 2017-02-14 | 2019-03-12 | 한국화학연구원 | 트리아졸로피리다진 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물 |
| CN109384774B (zh) * | 2017-08-11 | 2023-02-17 | 中国科学院上海药物研究所 | 一类多取代的吡嗪/三嗪酰胺类化合物及其制备方法和应用 |
| CN108530450B (zh) * | 2018-05-03 | 2021-03-30 | 赖建智 | 具有egfr抑制活性的化合物、制备方法及其在疾病治疗中的应用 |
| CN112469414A (zh) | 2018-05-25 | 2021-03-09 | 昂科库博疗法有限责任公司 | 作为新型候选抗癌药物的高效力tacc3抑制剂 |
| MX2021004191A (es) | 2018-10-15 | 2021-05-27 | Nurix Therapeutics Inc | Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma. |
| JP7631193B2 (ja) | 2018-10-22 | 2025-02-18 | アルミス インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用 |
| US12582722B2 (en) * | 2019-02-13 | 2026-03-24 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway |
| EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
| CA3136348A1 (fr) | 2019-04-09 | 2020-10-15 | Nurix Therapeutics, Inc. | Composes de piperidine substitues en position 3 pour l'inhibition de cbl-b, et utilisation d'un inhibiteur de cbl-b en combinaison avec un vaccin contre le cancer et/ou un virus o ncolytique |
| AU2020278592B2 (en) | 2019-05-17 | 2024-10-10 | Nurix Therapeutics, Inc. | Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof |
| MX2021015675A (es) | 2019-06-26 | 2022-02-03 | Nurix Therapeutics Inc | Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos. |
| EP4034140A1 (fr) | 2019-09-24 | 2022-08-03 | Nurix Therapeutics, Inc. | Inhibiteurs de cbl et compositions destinés à être utilisés dans une thérapie cellulaire adoptive |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| WO2021113557A1 (fr) | 2019-12-04 | 2021-06-10 | Nurix Therapeutics, Inc. | Composés bifonctionnels pour la dégradation de la btk par l'intermédiaire de la voie de l'ubiquitine-protéosome |
| WO2021148581A1 (fr) | 2020-01-22 | 2021-07-29 | Onxeo | Nouvelle molécule dbait et son utilisation |
| AU2021284676A1 (en) * | 2020-06-01 | 2023-02-02 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | New pyrazine compound |
| WO2022071772A1 (fr) * | 2020-09-29 | 2022-04-07 | (주)메디톡스 | Inhibiteur de protéine kinase et son utilisation |
| WO2022217123A2 (fr) | 2021-04-08 | 2022-10-13 | Nurix Therapeutics, Inc. | Polythérapies comprenant des composés inhibiteurs de cbl-b |
| KR20240005751A (ko) * | 2021-04-12 | 2024-01-12 | 에이2에이 파마수티칼스, 잉크. | 암 치료를 위한 조성물 및 방법 |
| JP2024524480A (ja) * | 2021-07-01 | 2024-07-05 | ハンチョウ、ヘルズン、セラピューティクス、カンパニー、リミテッド | ブルトン型チロシンキナーゼ及びその突然変異体の分解剤、組成物並びにそれらの応用 |
| CA3236073A1 (fr) | 2021-10-26 | 2023-05-04 | Robert J. Brown | Composes de piperidinylpyrazine-carboxamide pour le traitement et la prevention du cancer et pour la degradation de btk |
| CN116143757B (zh) * | 2021-11-22 | 2024-07-05 | 杭州和正医药有限公司 | 一种可降解btk激酶的多功能化合物、组合物及应用 |
| EP4499625A4 (fr) | 2022-03-24 | 2026-03-18 | A2A Pharmaceuticals Inc | Compositions et méthodes de traitement du cancer |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE288420T1 (de) * | 1999-06-09 | 2005-02-15 | Yamanouchi Pharma Co Ltd | Neuartige heterocyclische carboxamid-derivate |
| JP4622047B2 (ja) * | 1999-06-09 | 2011-02-02 | アステラス製薬株式会社 | 新規なヘテロ環カルボキサミド誘導体 |
| JP2014005206A (ja) * | 2010-10-22 | 2014-01-16 | Astellas Pharma Inc | アリールアミノヘテロ環カルボキサミド化合物 |
| WO2013047813A1 (fr) * | 2011-09-30 | 2013-04-04 | 大鵬薬品工業株式会社 | Dérivé de 1,2,4-triazine-6-carboxamide |
| US9216173B2 (en) * | 2011-10-05 | 2015-12-22 | Merck Sharp & Dohme Corp. | 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors |
| MX363551B (es) * | 2011-11-23 | 2019-03-27 | Portola Pharmaceuticals Inc Star | Compuestos derivados de pirazina como inhibidores de cinasa. |
| CN104159891B (zh) * | 2012-01-10 | 2016-09-07 | 霍夫曼-拉罗奇有限公司 | 哒嗪酰胺化合物和它们作为syk 抑制剂的用途 |
| EA026353B1 (ru) * | 2012-01-17 | 2017-03-31 | Астеллас Фарма Инк. | Соединение пиразинкарбоксамида |
| US20140113931A1 (en) * | 2012-06-22 | 2014-04-24 | Portola Pharmaceuticals, Inc. | Substituted picolinamide kinase inhibitors |
| US9040530B2 (en) * | 2012-06-22 | 2015-05-26 | Portola Pharmaceuticals, Inc. | 1,2,4-triazine-6-carboxamide kinase inhibitors |
| CN105073750A (zh) * | 2013-03-05 | 2015-11-18 | 豪夫迈·罗氏有限公司 | 布鲁顿氏酪氨酸激酶抑制剂 |
| WO2014153280A1 (fr) * | 2013-03-22 | 2014-09-25 | Merck Sharp & Dohme Corp. | Inhibiteurs de tyrosine kinase de la rate (syk) contenant du 2-pyridyl carboxamide |
| WO2015039613A1 (fr) * | 2013-09-18 | 2015-03-26 | 北京韩美药品有限公司 | Composé inhibant les activités kinase de btk et/ou jak3 |
| US9382246B2 (en) * | 2013-12-05 | 2016-07-05 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
-
2016
- 2016-06-02 MX MX2017015574A patent/MX2017015574A/es unknown
- 2016-06-02 EP EP16804424.6A patent/EP3310776A4/fr not_active Withdrawn
- 2016-06-02 KR KR1020177037849A patent/KR20180021740A/ko not_active Withdrawn
- 2016-06-02 AU AU2016270907A patent/AU2016270907B2/en not_active Ceased
- 2016-06-02 BR BR112017025986A patent/BR112017025986A2/pt not_active IP Right Cessation
- 2016-06-02 US US15/579,142 patent/US20180305348A1/en not_active Abandoned
- 2016-06-02 WO PCT/US2016/035489 patent/WO2016196776A2/fr not_active Ceased
- 2016-06-02 CN CN201680035113.2A patent/CN107709315A/zh active Pending
- 2016-06-02 RU RU2017145650A patent/RU2017145650A/ru not_active Application Discontinuation
- 2016-06-02 SG SG10201911523YA patent/SG10201911523YA/en unknown
- 2016-06-02 CA CA2987054A patent/CA2987054A1/fr not_active Abandoned
- 2016-06-02 MA MA042623A patent/MA42623A/fr unknown
- 2016-06-02 JP JP2017560655A patent/JP2018522823A/ja active Pending
-
2017
- 2017-11-21 IL IL255831A patent/IL255831A/en unknown
-
2019
- 2019-07-17 US US16/514,544 patent/US20210070748A1/en not_active Abandoned
-
2020
- 2020-12-11 AU AU2020286332A patent/AU2020286332A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016270907A1 (en) | 2017-12-07 |
| JP2018522823A (ja) | 2018-08-16 |
| AU2016270907B2 (en) | 2020-09-17 |
| CA2987054A1 (fr) | 2016-12-08 |
| IL255831A (en) | 2018-01-31 |
| AU2020286332A1 (en) | 2021-01-21 |
| RU2017145650A (ru) | 2019-07-15 |
| US20210070748A1 (en) | 2021-03-11 |
| EP3310776A2 (fr) | 2018-04-25 |
| RU2017145650A3 (fr) | 2019-11-22 |
| WO2016196776A2 (fr) | 2016-12-08 |
| MX2017015574A (es) | 2018-08-09 |
| WO2016196776A3 (fr) | 2017-01-05 |
| EP3310776A4 (fr) | 2019-01-16 |
| SG10201911523YA (en) | 2020-02-27 |
| US20180305348A1 (en) | 2018-10-25 |
| KR20180021740A (ko) | 2018-03-05 |
| CN107709315A (zh) | 2018-02-16 |
| BR112017025986A2 (pt) | 2018-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279258B (en) | tyrosine kinase inhibitors | |
| MA42623A (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
| MA42242A (fr) | Inhibiteurs de la tyrosine kinase | |
| EP3414234A4 (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
| MA43162A (fr) | Inhibiteurs de type imidazopyrazine de tyrosine kinase de bruton | |
| EP3541932A4 (fr) | Inhibiteurs de crispr-cas9 | |
| EP3347018A4 (fr) | Inhibiteurs de kinases cycline-dépendantes | |
| LT3580220T (lt) | Aminotriazolopiridinai, kaip kinazės inhibitoriai | |
| EP3405192A4 (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
| EP3283077A4 (fr) | Inhibiteurs de bromodomaine | |
| EP3247692A4 (fr) | Inhibiteurs de trka kinase | |
| DK3365334T3 (da) | Benzolactamforbindelser som proteinkinaseinhibitorer | |
| CL2016002502A1 (es) | Inhibidores de biaril cinasa | |
| HUE050842T2 (hu) | Janus-kináz inhibitor | |
| BR112017002232A2 (pt) | combinações de inibidor de tirosina quinase de bruton e usos das mesmas | |
| MA44474A (fr) | Nouveaux inhibiteurs de la ferroportine | |
| EP3442972A4 (fr) | Inhibiteurs de bromodomaine | |
| DK3290418T3 (da) | Janus Kinase (JAK)-hæmmere | |
| EP3313828A4 (fr) | Inhibiteurs de métallo-bêta-lactamases | |
| BR112017020743A2 (pt) | cocristais de um inibidor da tirosina cinase de bruton. | |
| LT3728207T (lt) | Chinazolinonai kaip parp14 inhibitoriai | |
| BR112017015206A2 (pt) | síntese de um inibidor de tirosina quinase de bruton | |
| LT3704118T (lt) | Aminoimidazopiridazinai, kaip kinazės inhibitoriai | |
| EP3349754A4 (fr) | Inhibiteurs de pcna | |
| MA43367A (fr) | Inhibiteurs de métallo-bêta-lactamases |